Tag: aphria

So far, November has been tough for the cannabis sector. Most cannabis companies have reported lower-than-expected earnings.

There seems to be no end to the cannabis sector’s woes. Several prominent cannabis players reported disappointing results in the latest earnings season.

Amid rising concerns about vaping-related deaths, President Trump recently announced that he'd meet with representatives of the vaping industry.

Aurora Cannabis (ACB) is set to report its fiscal 2020 first-quarter results on November 14, and investors are waiting with bated breath.

Analysts expect Cronos Group to report revenue of $14.62 million Canadian dollars in fiscal Q3 2019. This implies a YoY (year-over-year) rise of 288.74%.

Legal cannabis in Mexico is going through several twists and turns. The country first allowed medical marijuana in June 2017.

MedMen's disappointing fourth-quarter results caused the stock price to fall. The company missed analysts' revenue estimates for the quarter.

Aurora Cannabis has had a rough 2019. Its stock has slid 30.46% YTD on the TSE (Toronto Stock Exchange) and by 24.19% on the NYSE.

Aphria’s stock price has risen 8.9% since reporting its Q1 earnings on October 15. The cannabis sector's weakness offset some of these gains.

On November 4, Aphria (APHA) announced the receipt of a cultivation license from Health Canada for its Aphria Diamond cannabis greenhouse facility.